Market Overview

J.P. Morgan Maintains Neutral on Amicus Therapeutics (FOLD)

Share:

J.P. Morgan is out with its report today on Amicus Therapeutics (NASDAQ: FOLD), maintaining Neutral.

In a note to clients, J.P. Morgan writes, "We are Neutral on FOLD shares. Amicus' chaperone technology is a unique platform in biotech that could offer treatment for a wide range of diseases, including Fabry disease and Parkinson's disease. Longer term we think there is a good probability that Amigal for Fabry disease will be successful, and we expect other earlier stage compounds to move forward. However, we think the announcement that Plicera failed a phase 2 study in Gaucher disease was a negative announcement that may increase the discount on Amicus' technology until data from other programs are made available."

At the time of posting, shares of FOLD were trading at $7.26, up 0.69% from Monday's close.

 

Related Articles (FOLD)

View Comments and Join the Discussion!

Posted-In: Amicus Therapeutics J.P. MorganAnalyst Color Analyst Ratings

Latest Ratings

StockFirmActionPT
MRVLCFRAMaintains35.0
CSIQCFRAUpgrades22.0
MGNXSVB LeerinkMaintains27.0
EVCFRAMaintains43.0
RCUSSVB LeerinkReiterates42.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com